Sign Up to like & get
recommendations!
1
Published in 2021 at "Oncoimmunology"
DOI: 10.1080/2162402x.2021.1906500
Abstract: ABSTRACT Only a small subset of colorectal cancer (CRC) patients benefits from immunotherapies, comprising blocking antibodies (Abs) against checkpoint receptor “programmed-cell-death-1” (PD1) and its ligand (PD-L1), because most cases lack the required mutational burden and…
read more here.
Keywords:
ppar induces;
induces expression;
cancer;
tumor ... See more keywords